Advanced Hepatocellular Carcinoma (HCC), Colorectal Cancer Metastatic to Liver, Gastric Cancer Metastatic to Liver
Conditions
Brief summary
This is a first-in-human, Phase 1 open-label, multicenter, dose escalation, safety, pharmacodynamic, and PK study of exoASO-STAT6 (CDK-004) in patients with advanced Hepatocellular Carcinoma (HCC) and patients with liver metastases from either primary gastric cancer or colorectal cancer (CRC).
Detailed description
CDK-004 as an intravenous (IV) treatment for advanced hepatocellular carcinoma (HCC), and primary gastric cancer or CRC with secondary liver metastases. CDK-004 is an investigational therapeutic candidate consisting of cell-derived exosomes loaded with a synthetic lipid-tagged oligonucleotide. CDK-004 is designed to allow for specific delivery of the STAT6 anti-sense oligonucleotide (ASO) to the myloid to repolarize macrophage from immune suppressive M2 to proinflammatory M1 phenotype, with a potential for meaningful single agent antitumor activity which has not been observed with other pathway inhibitors to date. CDK-004 will be administered as a single agent intravenously (IV) at various doses. Dose limiting toxicities (DLTs) will be assessed during the study.
Interventions
DRUGCDK-004
ASO-STAT6 exosome administered Intravenously
Sponsors
Codiak BioSciences
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Must have one of the following cancer types: 1. Advanced HCC defined as Barcelona Clinic Liver Cancer (BCLC) Stage B/C not amenable to resection or locoregional therapy; 2. Histologic or radiologic proof of liver metastasis from primary CRC which is unresectable with no evidence of extrahepatic metastasis; 3. Histologic or radiologic proof of liver metastasis from primary gastric cancer which is unresectable with no evidence of extrahepatic metastasis. 2. Documented progression after at least 1 line of FDA approved systemic therapy for advanced HCC/gastric cancer/CRC or intolerable/refuse to chemotherapy. 3. ≥ 18 years of age at screening. 4. Measurable disease by RECIST v1.1. 5. Able to provide archival tumor tissue/fresh biopsy prior to study treatment and on-treatment tumor biopsies if considered safe and medically feasible by the Investigator. 6. ECOG performance status of 0-2. 7. Acceptable liver function 8. Acceptable renal function 9. Acceptable hematologic status 10. Cirrhosis classified as Child-Pugh Class A (applicable only to patients diagnosed with cirrhosis).. 11. Women of child-bearing potential agree to use highly effective contraceptive methods and avoid egg donation and preservation during the study treatment and for 6 months after the last dose of study drug. 12. Men of child-producing potential agree to use highly effective contraceptive methods and avoid sperm donation and preservation during the study treatment and for 6 months after the last dose of study drug.
Exclusion criteria
1. Treatment with any systemic or liver-directed anticancer therapy within 3 weeks of the first dose of study drug. 2. Uncontrolled partial or complete biliary obstruction. 3. Left ventricular ejection fraction (LVEF) \< 50% at Screening. 4. 12-lead ECG demonstrating QT interval corrected by Fridericia's formula (QTcF) \> 480 ms or history of long QTc syndrome. 5. Ongoing, clinically significant AEs due to prior anticancer therapies. 6. Patients with history of another primary cancer, including co-existent second malignancy, with the exception of: a) curatively resected non-melanoma skin cancer; b) curatively treated cervical carcinoma in situ; or c) other primary solid tumor with no known active disease present or in the opinion of the Investigator will not affect patient outcome. 7. Known clinically active brain metastases or known carcinomatous meningitis/leptomeningeal disease. 8. Known clinically significant infection. 9. Known clinically significant cardiac disease, including unstable angina or has had a procedure to address the underlying cause and has experienced angina within 4 weeks prior to Cycle 1 Day 1, acute myocardial infarction within 6 months from Day 1 of study drug administration, or New York Heart Association Class III or IV congestive heart failure. 10. Known history of human immunodeficiency virus (HIV). 11. If history of concurrent Hepatitis B virus (HBV) or Hepatitis C virus (HCV) infection, meets the following criteria: patients with detectable hepatitis B surface antigen (HbsAg) or detectable HBV DNA should be managed per local treatment guidelines. Controlled (treated) hepatitis B patients will be allowed if they started treatment at the time of consent and treatment is continued during study participation; patients with hepatitis C and detectable RNA are eligible if antiviral therapy has been completed prior to first administration of study drug. Testing does not need to be conducted at Screening if results from testing within the past 12 months are available. 12. History of liver transplant. 13. History of immunodeficiency or is receiving chronic systemic steroid therapy 14. Poorly controlled diabetes mellitus. 15. Active or previously documented autoimmune or inflammatory diseases 16. Is currently participating in a study of an investigational therapy or device or has participated and received an investigation therapy or device within 3 weeks of administration of CDK-004. 17. Has another physical or mental health disorder that might cause difficulty in obtaining informed consent and/or participation in the trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To characterize the safety and tolerability of CDK-004. | Up to 2 years | Incidence of treatment-emergent adverse events as assessed by CTCAE 5.0. |
Countries
United States
Outcome results
None listed